Clinical Trials
3 trialsNCT07187674 2025-09-23
The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel
Harbin Medical University
Phase NA Not yet recruiting
NCT04801966 2023-05-10
TAILOR
Peter MacCallum Cancer Centre, Australia
Phase NA Terminated
NCT02681237 2022-05-09
A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer
University Health Network, Toronto
Phase NA Completed